Pharmaco-electroencephalography


is the science of recording the spontaneous rhythmic electrical activity of a living brain through electrodes on the scalp. Brain rhythms have origins similar to the electrical activity of the heart. The rhythmic activity varies in frequency and amplitude with age, attention, sleep, and chemical concentrations of oxygen, carbon dioxide, glucose, ammonia, and hormones. Chemicals that affect brain functions change brain rhythms in systematic and identifiable ways. As new psychoactive drugs were discovered that changed behavior, the basis for the science of psychopharmacology, the accompanying changes in the rhythms were found to be drug class specific. The measurement of the changes in rhythms became the basis for the science of pharmaco-EEG.
Definitions of the changes in EEG rhythms were developed that identified and classified psychoactive drugs, monitored the depth of anesthesia, and evaluated the efficacy of the seizures induced in convulsive therapy.

History

The first recordings of electrical activity from the brain were reported from exposed animal brain tissues in the 1870s. In 1929 Hans Berger, a German psychiatrist, reported continuous electrical rhythms from the intact human head using electrodes on the scalp. The continuous electrical activity varied in frequencies and amplitude with drowsiness and sleep, and with mental problem solving. Episodic runs and bursts of high voltage slow frequencies were recorded in patients with epilepsy.
In his third report in 1931 Berger recorded changes in the rhythms with cocaine, morphine, scopolamine, and chloroform. Each chemical elicited different frequency and amplitude patterns and different behaviors.
The first clinical applications were in identifying the sudden bursts of high voltage slow frequencies during seizures, both spontaneous and induced by the chemical pentylenetetrazol, by electricity in electroshock, and in the coma induced by insulin. When reserpine was studied in 1953, chlorpromazine in 1954, and imipramine in 1957, individual rhythmic patterns were described.
The EEG patterns of new psychoactive drugs predicted their clinical activity. By the 1960s, EEG analysis of psychoactive drugs was a feature of the NIMH Early Clinical Drug Evaluation program that evaluated and identified new psychiatric treatments. Proposed psychoactive drugs developed in chemical laboratories were first tested in animals and then tested in man. The changes in the EEG became the basis for a classification of new drugs.
Assessment methods in human volunteers were developed that recorded the changes in the resting subject at different dosages, both on acute single administrations and repeated daily dosing. The observed changes were compared to those for known drugs and predicted their behavioral effects. When no systematic changes were recorded, the agents were considered not to have a clinical use.
Dosing schedules were optimized. In patients who failed to respond to prescribed treatments, those who were considered "pharmacotherapy resistant," EEG studies showed that the chemicals did not elicit identifiable brain changes.
In pre-clinical animal trials EEG recordings were associated the changes with vigilance and motor measures, concluding that the EEG patterns were "dissociated," that is, bearing little relationship to the changes in behavior. In human trials, however, when the EEG measures could be related to vigilance, mood, memory, and psychological tests, a theory of "association of EEG and behavior" developed and sustained pharmaco-EEG studies of new drugs.
The technology was applied in anesthesia, identifying the efficacy of individual seizures in convulsive therapy, in studies of sleep patterns, and the relation of evoked potentials to speech and psychological tests.
Social changes in attitudes to the ethics of testing drugs and treatments in patients, prisoners, children, and volunteers inhibited the continued development of the science and its abandonment.

Methodology

Polypharmacy and the widespread use of active psychiatric drugs made the study of individual compounds in psychiatric patients difficult. The science then successfully focused on alert male volunteers.
Vigilance. The scalp recorded EEG is sensitive to changes in vigilance. Different methods developed to sustain a monitored level of alertness using hand held buzzers that sounded off when the subject relaxed and dozed.
Volunteer Baseline and Placebo training. As the EEG is sensitive to anxiety, an initial training session became standard procedure. The baseline recording identified subjects whose records were unique.
EEG recording. Different electrode placements were tested. Commonly the recordings were made using the frontal-occipital or the bifrontal leads. Standard EEG amplifiers were used.
Quantification and analyses. In the beginning the EEG recordings were made on paper and changes measured visually, scored by ruler and calipers. By the 1960s, electronic analyzers of 10 second epochs measured changes in "power." Digital computer methods using period analysis, power spectral density, and amplitude analyses followed.
The quantitative changes in mean frequency, mean amplitudes, percent time delta, theta, alpha, beta1, and beta2, and the presence of bursts in 10-second epochs were commonly used to identify patterns.
Predictive patterns. The measures related the EEG changes to the common classes of psychoactive drugs—antidepressant, anxiolytic, antipsychotic, hallucinogen, deliriant, euphoriant, and mood stabilizer being the most frequent. For a time, the pharmaco-EEG profiles of different classes of drugs were actively used to identify active psychotropic agents.

Applications

Psychopharmacology. Pharmaco-EEG studies were economically useful in clinically classifying new agents, dosage ranges and durations of effects, and separating active from inactive substances. The list of successful applications is extensive; some specific examples are the identification of mianserin and doxepin as antidepressants of the imipramine class; of the inactivity of flutroline as a proposed antipsychotic in man despite activity in dogs; and of equivalent EEG activity of the laevo and dextro enantiomers of 6-azamianserin despite differences in preclinical trials.
Studies of different cannabis formulations and opioid substitutes in the treatment of opioid dependence, the quantitative EEG experiments showed the efficiency of antagonistic and replacement activity of different dosing schedules. Dose finding trials of naloxone showed no specific CNS effect when administered alone but very effective antagonistic action in opioid dose and overdose.
Convulsive therapy. The grandmal seizure is the central event in electroshock and insulin coma. It was introduced in 1934 and by the 1940s EEG recordings during the treatment showed the classic sequence of epileptic seizure events recognized as the "grand mal seizure." In the 1950s, recordings of interseizure records, on days after an induced seizure, showed progressive slowing of mean frequencies and increased amplitudes during the treatment course. These changes were necessary accompaniments of effective courses of treatment—patients without progressive slowing failed to recover.
In the early 1980s, commercial ECT devices were equipped with a 2-channel EEG recorder that measured the EEG characteristics and duration. The quality of the EEG record became the standard for an "effective" treatment. The same quantitative measures used in psychopharmacology were established in clinical ECT.
Anesthesia. Specialized equipment to monitor ongoing identification of anesthesia stages are common in modern surgical units.